Fate Therapeutics Inc.

77.99-1.02-1.29%Vol 778.33K1Y Perf 185.38%
Apr 9th, 2021 16:00 DELAYED
BID77.00 ASK78.74
Open78.32 Previous Close79.01
Pre-Market- After-Market77.99
 - -  - -%
Target Price
110.07 
Analyst Rating
Strong Buy 1.25
Potential %
41.13 
Finscreener Ranking
★★★★+     56.10
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★+     53.80
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★     60.50
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap7.31B 
Earnings Rating
Sell
Price Range Ratio 52W %
54.82 
Earnings Date
10th May 2021

Today's Price Range

76.1780.80

52W Range

25.60121.16

5 Year PE Ratio Range

-11.60-3.20

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-4.79%
1 Month
-13.20%
3 Months
-32.95%
6 Months
62.45%
1 Year
185.38%
3 Years
675.25%
5 Years
3 544.39%
10 Years
-

TickerPriceChg.Chg.%
FATE77.99-1.0200-1.29
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Financial StrengthValueIndustryS&P 500US Markets
5.70
5.80
0.20
0.25
-275.20
Leverage Ratio 1.50
ProfitabilityValueIndustryS&P 500US Markets
-
-807.20
-791.70
-936.40
-
RevenueValueIndustryS&P 500US Markets
28.92M
0.31
99.76
46.77
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.38-0.380.00
Q03 2020-0.29-0.36-24.14
Q02 2020-0.20-0.35-75.00
Q01 2020-0.38-0.44-15.79
Q04 2019-0.39-0.375.13
Q03 2019-0.38-0.40-5.26
Q02 2019-0.32-0.36-12.50
Q01 2019-0.23-0.30-30.43
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.43-4.88Negative
6/2021 QR-0.44-4.76Negative
12/2021 FY-1.84-4.55Negative
12/2022 FY-2.22-12.69Negative
Next Report Date10th May 2021
Estimated EPS Next Report-0.43
Estimates Count9
EPS Growth Next 5 Years %-
Volume Overview
Volume778.33K
Shares Outstanding93.78M
Trades Count13.20K
Dollar Volume116.79M
Avg. Volume1.07M
Avg. Weekly Volume644.95K
Avg. Monthly Volume1.05M
Avg. Quarterly Volume996.14K

Fate Therapeutics Inc. (NASDAQ: FATE) stock closed at 77.99 per share at the end of the most recent trading day (a -1.29% change compared to the prior day closing price) with a volume of 778.65K shares and market capitalization of 7.31B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 279 people. Fate Therapeutics Inc. CEO is J. Scott Wolchko.

The one-year performance of Fate Therapeutics Inc. stock is 185.38%, while year-to-date (YTD) performance is -14.23%. FATE stock has a five-year performance of 3544.39%. Its 52-week range is between 25.6 and 121.16, which gives FATE stock a 52-week price range ratio of 54.82%

Fate Therapeutics Inc. currently has a PE ratio of -39.40, a price-to-book (PB) ratio of 20.11, a price-to-sale (PS) ratio of 265.63, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -36.44%, a ROC of -36.97% and a ROE of -53.28%. The company’s profit margin is -%, its EBITDA margin is -791.70%, and its revenue ttm is $28.92 Million , which makes it $0.31 revenue per share.

Of the last four earnings reports from Fate Therapeutics Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.43 for the next earnings report. Fate Therapeutics Inc.’s next earnings report date is 10th May 2021.

The consensus rating of Wall Street analysts for Fate Therapeutics Inc. is Strong Buy (1.25), with a target price of $110.07, which is +41.13% compared to the current price. The earnings rating for Fate Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Fate Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Fate Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 12.98, ATR14 : 9.21, CCI20 : -85.67, Chaikin Money Flow : -0.07, MACD : -3.97, Money Flow Index : 41.00, ROC : -12.32, RSI : 44.79, STOCH (14,3) : 34.38, STOCH RSI : 0.77, UO : 51.23, Williams %R : -65.62), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Fate Therapeutics Inc. in the last 12-months were: Bahram Valamehr (Option Excercise at a value of $68 778), Bahram Valamehr (Sold 83 884 shares of value $6 729 621 ), Cindy Tahl (Option Excercise at a value of $471 750), Cindy Tahl (Sold 179 483 shares of value $11 573 326 ), Daniel D. Shoemaker (Sold 84 482 shares of value $5 336 625 ), J. Scott Wolchko (Option Excercise at a value of $760 308), J. Scott Wolchko (Sold 229 407 shares of value $21 102 772 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
14 (87.50 %)
15 (88.24 %)
14 (87.50 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (12.50 %)
2 (11.76 %)
2 (12.50 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.25
Strong Buy
1.24
Strong Buy
1.25

Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

CEO: J. Scott Wolchko

Telephone: +1 858 875-1800

Address: 3535 General Atomics Court, San Diego 92121, CA, US

Number of employees: 279

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

65%35%

Bearish Bullish

50%50%

Bearish Bullish

47%53%

News

Stocktwits